9 results on '"Bianco AC"'
Search Results
2. Primary hypothyroidism and quality of life.
- Author
-
Hegedüs L, Bianco AC, Jonklaas J, Pearce SH, Weetman AP, and Perros P
- Subjects
- Hormone Replacement Therapy, Humans, Thyrotropin, Thyroxine therapeutic use, Triiodothyronine, Hypothyroidism diagnosis, Hypothyroidism drug therapy, Quality of Life
- Abstract
In the 1970s, treatment with thyroid extract was superseded by levothyroxine, a synthetic L form of tetraiodothyronine. Since then, no major innovation has emerged for the treatment of hypothyroidism. The biochemical definition of subclinical hypothyroidism is a matter of debate. Indiscriminate screening for hypothyroidism has led to overdiagnosis and treatment initiation at lower serum levels of thyroid-stimulating hormone (TSH) than previously. Adverse health effects have been documented in individuals with hypothyroidism or hyperthyroidism, and these adverse effects can affect health-related quality of life (QOL). Levothyroxine substitution improves, but does not always normalize, QOL, especially for individuals with mild hypothyroidism. However, neither studies combining levothyroxine and liothyronine (the synthetic form of tri-iodothyronine) nor the use of desiccated thyroid extract have shown robust improvements in patient satisfaction. Future studies should focus not only on a better understanding of an individual's TSH set point (the innate narrow physiological range of serum concentration of TSH in an individual, before the onset of hypothyroidism) and alternative thyroid hormone combinations and formulations, but also on autoimmunity and comorbidities unrelated to hypothyroidism as drivers of patient dissatisfaction. Attention to the long-term health consequences of hypothyroidism, beyond QOL, and the risks of overtreatment is imperative., (© 2022. Springer Nature Limited.)
- Published
- 2022
- Full Text
- View/download PDF
3. Neonatal thyroxine activation modifies epigenetic programming of the liver.
- Author
-
Fonseca TL, Garcia T, Fernandes GW, Nair TM, and Bianco AC
- Subjects
- Animals, Animals, Newborn, Chromatin metabolism, DNA Methylation, Gene Expression, Gene Expression Regulation, Developmental, Iodide Peroxidase genetics, Iodide Peroxidase metabolism, Liver growth & development, Mice, Mice, Knockout, Iodothyronine Deiodinase Type II, Epigenesis, Genetic, Liver metabolism, Triiodothyronine metabolism
- Abstract
The type 2 deiodinase (D2) in the neonatal liver accelerates local thyroid hormone triiodothyronine (T3) production and expression of T3-responsive genes. Here we show that this surge in T3 permanently modifies hepatic gene expression. Liver-specific Dio2 inactivation (Alb-D2KO) transiently increases H3K9me3 levels during post-natal days 1-5 (P1-P5), and results in methylation of 1,508 DNA sites (H-sites) in the adult mouse liver. These sites are associated with 1,551 areas of reduced chromatin accessibility (RCA) within core promoters and 2,426 within intergenic regions, with reduction in the expression of 1,363 genes. There is strong spatial correlation between density of H-sites and RCA sites. Chromosome conformation capture (Hi-C) data reveals a set of 81 repressed genes with a promoter RCA in contact with an intergenic RCA ~300 Kbp apart, within the same topologically associating domain (χ
2 = 777; p < 0.00001). These data explain how the systemic hormone T3 acts locally during development to define future expression of hepatic genes., (© 2021. The Author(s).)- Published
- 2021
- Full Text
- View/download PDF
4. Publisher Correction: Accelerating functional gene discovery in osteoarthritis.
- Author
-
Butterfield NC, Curry KF, Steinberg J, Dewhurst H, Komla-Ebri D, Mannan NS, Adoum AT, Leitch VD, Logan JG, Waung JA, Ghirardello E, Southam L, Youlten SE, Wilkinson JM, McAninch EA, Vancollie VE, Kussy F, White JK, Lelliott CJ, Adams DJ, Jacques R, Bianco AC, Boyde A, Zeggini E, Croucher PI, Williams GR, and Bassett JHD
- Published
- 2021
- Full Text
- View/download PDF
5. Accelerating functional gene discovery in osteoarthritis.
- Author
-
Butterfield NC, Curry KF, Steinberg J, Dewhurst H, Komla-Ebri D, Mannan NS, Adoum AT, Leitch VD, Logan JG, Waung JA, Ghirardello E, Southam L, Youlten SE, Wilkinson JM, McAninch EA, Vancollie VE, Kussy F, White JK, Lelliott CJ, Adams DJ, Jacques R, Bianco AC, Boyde A, Zeggini E, Croucher PI, Williams GR, and Bassett JHD
- Subjects
- Animals, Bone and Bones pathology, CRISPR-Cas Systems, Cartilage pathology, Clustered Regularly Interspaced Short Palindromic Repeats, Disease Models, Animal, Drug Discovery, Gene Editing, Gonadotropin-Releasing Hormone genetics, Iodide Peroxidase, Mice, Mice, Knockout, Osteoarthritis pathology, Osteoarthritis surgery, Paired Box Transcription Factors genetics, Phenotype, Iodothyronine Deiodinase Type II, Genetic Association Studies, Genetic Predisposition to Disease genetics, Osteoarthritis genetics
- Abstract
Osteoarthritis causes debilitating pain and disability, resulting in a considerable socioeconomic burden, yet no drugs are available that prevent disease onset or progression. Here, we develop, validate and use rapid-throughput imaging techniques to identify abnormal joint phenotypes in randomly selected mutant mice generated by the International Knockout Mouse Consortium. We identify 14 genes with functional involvement in osteoarthritis pathogenesis, including the homeobox gene Pitx1, and functionally characterize 6 candidate human osteoarthritis genes in mouse models. We demonstrate sensitivity of the methods by identifying age-related degenerative joint damage in wild-type mice. Finally, we phenotype previously generated mutant mice with an osteoarthritis-associated polymorphism in the Dio2 gene by CRISPR/Cas9 genome editing and demonstrate a protective role in disease onset with public health implications. We hope this expanding resource of mutant mice will accelerate functional gene discovery in osteoarthritis and offer drug discovery opportunities for this common, incapacitating chronic disease.
- Published
- 2021
- Full Text
- View/download PDF
6. Levothyroxine treatment and cholesterol in hypothyroidism.
- Author
-
Bianco AC and Taylor P
- Subjects
- Animals, Humans, Hypercholesterolemia blood, Hypothyroidism, Thyrotropin blood, Cholesterol blood, Thyroxine therapeutic use
- Published
- 2020
- Full Text
- View/download PDF
7. Urgent need for further research in subclinical hypothyroidism.
- Author
-
Taylor P and Bianco AC
- Subjects
- Humans, Thyroid Hormones, Thyrotropin, Hypothyroidism
- Published
- 2019
- Full Text
- View/download PDF
8. Scope and limitations of iodothyronine deiodinases in hypothyroidism.
- Author
-
Gereben B, McAninch EA, Ribeiro MO, and Bianco AC
- Subjects
- Animals, Brain Diseases etiology, Brain Diseases genetics, Humans, Hypothyroidism drug therapy, Hypothyroidism genetics, Hypothyroidism psychology, Iodide Peroxidase genetics, Thyroid Hormones metabolism, Thyroid Hormones therapeutic use, Iodothyronine Deiodinase Type II, Hypothyroidism enzymology, Iodide Peroxidase metabolism
- Abstract
The coordinated expression and activity of the iodothyronine deiodinases regulate thyroid hormone levels in hypothyroidism. Once heralded as the pathway underpinning adequate thyroid-hormone replacement therapy with levothyroxine, the role of these enzymes has come into question as they have been implicated in both an inability to normalize serum levels of tri-iodothyronine (T3) and the incomplete resolution of hypothyroid symptoms. These observations, some of which were validated in animal models of levothyroxine monotherapy, challenge the paradigm that tissue levels of T3 and thyroid-hormone signalling can be fully restored by administration of levothyroxine alone. The low serum levels of T3 observed among patients receiving levothyroxine monotherapy occur as a consequence of type 2 iodothyronine deiodinase (DIO2) in the hypothalamus being fairly insensitive to ubiquitination. In addition, residual symptoms of hypothyroidism have been linked to a prevalent polymorphism in the DIO2 gene that might be a risk factor for neurodegenerative disease. Here, we discuss how these novel findings underscore the clinical importance of iodothyronine deiodinases in hypothyroidism and how an improved understanding of these enzymes might translate to therapeutic advances in the care of millions of patients with this condition.
- Published
- 2015
- Full Text
- View/download PDF
9. Reawakened interest in type III iodothyronine deiodinase in critical illness and injury.
- Author
-
Huang SA and Bianco AC
- Subjects
- Animals, Euthyroid Sick Syndromes blood, Euthyroid Sick Syndromes metabolism, Euthyroid Sick Syndromes pathology, Humans, Iodide Peroxidase blood, Thyroid Hormones blood, Critical Illness, Iodide Peroxidase metabolism, Thyroid Hormones metabolism, Wounds and Injuries enzymology
- Abstract
Thyroid hormones influence gene expression in virtually all vertebrate tissues. Precise regulation of the active endogenous ligand, 3,5,3'-triiodothyronine (T(3)), is achieved by the sequential removal of iodine moieties from the thyroid hormone molecule. Type III iodothyronine deiodinase (D3) is the major inactivating enzyme terminating the action of T(3) and preventing activation of the prohormone, thyroxine (T(4)). Recent studies have revealed the induction of high D3 activity in diverse animal models of tissue injury including starvation, cryolesion, cardiac hypertrophy, infarction, and chronic inflammation. By analyzing serum and tissues taken from hospitalized patients at the time of death, investigators have also documented the robust induction of D3 activity in several human tissues that normally have none, including the liver and skeletal muscle, and shown clinically relevant consequences to systemic thyroid status. These studies reveal a novel role of D3 in the tissue response to injury and in the derangement of thyroid hormone homeostasis commonly observed during critical illness.
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.